HMGB1 and renal cell carcinoma: In a clinicopathological analysis including 80 patients with renal cell carcinoma, elevated HMGB1 levels were significantly associated with unfavorable clinical outcomes, and this manifestation appeared to be achieved by affecting the receptor product of glycosylation endpoints(RAGE) (74).